Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMesoblast Ltd

Mesoblast Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
14.27 USD 0.17 ( 1.21%)
Last update at 2026-11-06T21:01:00Z
VOLUME
192707
Market Cap
1914.06M

Momentum Score

…

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.82
Low
14.30
High
52 Week Price Range
13.05
Low
21.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
14.10
Dividend Yield
-
Revenue TTM
120.25M
Revenue Per Share
0.93
Gross Profit TTM
96.22M
Debt / Equity
0.22
ROE
-9.86%
Net Debt
79.94M
ROCE
-7.44%
Diluted EPS TTM
-0.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -57.14M -101.81M -88.15M -82.10M -91.59M
Net income -57.76M -102.14M -87.96M -81.89M -91.35M
Selling general administrative 57.35M 23.21M 11.84M 25.37M 27.21M
Selling and marketing expenses - 16.10M 11.79M 27.73M 30.76M
Gross profit 101.58M 12.07M -35.17M 7.50M 10.21M
Reconciled depreciation - 6.40M 4.67M 4.11M 4.38M
Ebit -51.50M -80.06M -57.97M -69.14M -80.95M
Ebitda -42.88M -73.66M -56.08M -65.03M -76.57M
Depreciation and amortization 8.62M 6.40M 1.90M 4.11M 4.38M
Operating income -51.50M -62.44M -84.15M -69.14M -80.95M
Other operating expenses 172.29M 79.64M 90.05M 76.79M 90.78M
Interest expense 23.95M 22.93M 20.66M 19.44M 16.91M
Tax provision 0.61M 0.33M -0.19M -0.21M -0.24M
Interest income 3.91M 3.55M 1.82M 0.83M 0.00M
Net interest income -17.96M -19.00M -18.83M -19.29M -17.29M
Income tax expense 0.62M 0.33M -0.19M -0.21M -0.24M
Total revenue 120.79M 17.20M 5.90M 7.50M 10.21M
Total operating expenses 153.08M 74.51M 48.98M 76.79M 90.78M
Cost of revenue 19.21M 5.13M 41.07M - -
Total other income expense net -5.64M -39.37M -4.00M 6.48M -10.63M
Net income from continuing ops -57.50M -102.14M -87.96M -81.89M -91.35M
Net income applicable to common shares - - - -81.89M -91.35M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 773.08M 784.68M 669.15M 669.41M 662.14M
Intangible assets 431.92M 437.37M 441.28M 442.73M 444.20M
Other current assets 64.33M 6.08M 2.55M 1.42M 5.40M
Total liab 204.67M 187.24M 188.80M 167.58M 165.10M
Total stockholder equity 568.40M 597.44M 480.36M 501.84M 497.04M
Other current liab 32.98M 26.71M 49.69M 5.43M 20.09M
Common stock 1530.77M 1508.85M 1310.81M 1249.12M 1165.31M
Capital stock 1530.77M 1508.85M 1310.81M 1249.12M 1165.31M
Retained earnings -1068.40M -1010.90M -908.76M -820.80M -738.92M
Other liab - - - 19.11M 15.02M
Good will 134.45M 134.45M 134.45M 134.45M 134.45M
Other assets - - - 2.33M 1.93M
Cash 47.39M 161.16M 62.56M 70.92M 60.03M
Total current liabilities 81.11M 102.63M 73.24M 41.98M 51.37M
Current deferred revenue - - - 6.40M -
Net debt 79.94M -33.00M 56.36M 45.58M 46.87M
Short term debt 13.63M 56.84M 16.49M 10.01M 8.20M
Short long term debt 10.60M 54.16M 13.86M 5.95M 5.02M
Short long term debt total 127.33M 128.16M 118.92M 116.50M 106.91M
Other stockholder equity - - - 73.52M 1235.96M
Property plant equipment - - - 6.49M 9.96M
Total current assets 197.49M 204.35M 86.46M 81.66M 69.84M
Long term investments 0.00M 1.39M 1.01M 1.76M 1.76M
Net tangible assets - - - -75.34M -81.61M
Net receivables 57.66M 14.87M 20.95M 7.00M 4.40M
Long term debt 108.64M 67.74M 100.48M 102.81M 91.62M
Inventory 28.11M 22.25M - - -
Accounts payable 34.51M 19.08M 7.07M 20.14M 23.08M
Accumulated other comprehensive income 106.03M 99.50M 78.30M 73.52M 70.65M
Non currrent assets other 1.20M 1.30M 2.10M 0.48M 1.93M
Non current assets total 575.59M 580.33M 582.69M 587.76M 592.30M
Capital lease obligations 8.10M 6.26M 4.58M 7.73M 10.27M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -0.12M 0.12M -0.10M -0.19M -0.23M
Change to liabilities - - - -0.40M 4.78M
Total cashflows from investing activities -1.02M 0.12M -0.10M -0.19M -0.23M
Net borrowings -5.94M -9.77M -13.52M -2.66M -6.33M
Total cash from financing activities -15.33M 147.34M 40.25M 74.50M -9.87M
Change to operating activities - - - 0.43M -0.05M
Net income -57.50M -102.14M -87.96M -81.89M -91.35M
Change in cash -58.64M 98.59M -8.36M 10.87M -76.43M
Begin period cash flow 161.55M 62.96M 71.32M 60.45M 136.88M
End period cash flow 102.91M 161.55M 62.96M 71.32M 60.45M
Total cash from operating activities -43.83M -49.95M -48.46M -63.27M -65.78M
Issuance of capital stock 2.60M 161.21M 65.41M 88.64M 0.21M
Depreciation - 6.40M 4.67M 4.11M 4.38M
Other cashflows from investing activities -0.07M 0.56M -0.06M 0.12M 0.12M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - 0.83M 0.00M - -
Change to account receivables - 6.29M -15.47M -0.12M 0.14M
Other cashflows from financing activities -23.64M -4.10M -11.63M -11.48M 48.17M
Change to netincome - - - 16.98M 16.32M
Capital expenditures 0.90M 0.73M 0.33M 0.31M 0.23M
Change in working capital - -3.04M -2.63M -2.47M 4.87M
Stock based compensation - 22.09M 5.87M 3.65M 5.54M
Other non cash items -43.83M 26.41M 31.78M 13.54M 11.02M
Free cash flow -44.73M -50.68M -48.79M -63.58M -66.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MESO
Mesoblast Ltd		 0.17
1.21%		 14.27 - 454.55 15.92 3.43 17.04 -6.55
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Mesoblast Ltd

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

55 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9639 6036

https://www.mesoblast.com

108

Name Title Year Born
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director 1957
Dr. Eric A. Rose M.D. Chief Medical Officer & Exec. Director 1951
Mr. Andrew Chaponnel B.Com. Interim Chief Fin. Officer NA
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. Chief Operating Officer 1964
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) Gen. Counsel & Corp. Exec. 1968
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders NA
Mr. Michael Schuster M.B.A., MS, BSc, MBA Head of Pharma Partnering 1977
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA Head of Regulatory Affairs & Quality Management NA
Mr. Justin Horst B.S. Head of Manufacturing NA
Ms. Niva Sivakumar B.Com., L.L.B. Joint Company Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…